Modulation of the cellular immune system by intravenous immunoglobulin - PubMed (original) (raw)

Review

. 2008 Dec;29(12):608-15.

doi: 10.1016/j.it.2008.08.004. Epub 2008 Oct 14.

Affiliations

• PMID: 18926775
• DOI: 10.1016/j.it.2008.08.004

Review

Modulation of the cellular immune system by intravenous immunoglobulin

Thanyalak Tha-In et al. Trends Immunol. 2008 Dec.

Abstract

Intravenous immunoglobulin (IVIg) is therapeutically used in a variety of immune-mediated diseases. The beneficial effects of IVIg in auto-antibody-mediated diseases can be explained by neutralization, accelerated clearance and prevention of Fcgamma-receptor binding of auto-antibodies. However, the means by which IVIg exerts therapeutic effects in disorders mediated by cellular immunity have remained enigmatic. Clinical improvements, followed by IVIg treatment, often extend beyond the half-life of infused IgG, thereby indicating that IVIg modifies the cellular immune compartment for a prolonged period. Here, we discuss recent advances in the understanding of different, mutually non-exclusive mechanisms of action of IVIg on cells of the innate and adaptive immune system. These mechanisms might explain the beneficial effects of IVIg in certain autoimmune and inflammatory diseases.

PubMed Disclaimer

Similar articles

• Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
  Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mouthon L, et al. Clin Exp Immunol. 1996 May;104 Suppl 1:3-9. Clin Exp Immunol. 1996. PMID: 8625540 Review.
• Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
  Crow AR, Song S, Siragam V, Lazarus AH. Crow AR, et al. Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):710-3. doi: 10.1002/pbc.20980. Pediatr Blood Cancer. 2006. PMID: 16933274 Review.
• IVIG therapy: interfering with interferon-gamma.
  Clynes R. Clynes R. Immunity. 2007 Jan;26(1):4-6. doi: 10.1016/j.immuni.2007.01.006. Immunity. 2007. PMID: 17241954 Review.
• [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
  Graff-Dubois S, Sibéril S, Elluru S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV. Graff-Dubois S, et al. Transfus Clin Biol. 2007 May;14(1):63-8. doi: 10.1016/j.tracli.2007.04.003. Epub 2007 May 10. Transfus Clin Biol. 2007. PMID: 17498995 Review. French.

Cited by

• Restoring immune tolerance in pemphigus vulgaris.
  Ahmed AR, Kalesinskas M, Kaveri SV. Ahmed AR, et al. Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2317762121. doi: 10.1073/pnas.2317762121. Epub 2024 Jan 23. Proc Natl Acad Sci U S A. 2024. PMID: 38261616 Free PMC article.
• Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.
  Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifirò G, De Luca A. Crisafulli S, et al. CNS Drugs. 2024 Jan;38(1):15-32. doi: 10.1007/s40263-023-01059-8. Epub 2024 Jan 11. CNS Drugs. 2024. PMID: 38212553 Review.
• Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed?
  Habibabady Z, McGrath G, Kinoshita K, Maenaka A, Ikechukwu I, Elias GF, Zaletel T, Rosales I, Hara H, Pierson RN 3rd, Cooper DKC. Habibabady Z, et al. Xenotransplantation. 2023 Jul-Aug;30(4):e12816. doi: 10.1111/xen.12816. Epub 2023 Aug 7. Xenotransplantation. 2023. PMID: 37548030 Free PMC article. Review.
• Intravenous Immunoglobulin for Autoimmune Bullous Diseases: A Case Series from a Central European Referral Center.
  Spałek MM, Bowszyc-Dmochowska M, Dmochowski M. Spałek MM, et al. Medicina (Kaunas). 2023 Jul 7;59(7):1265. doi: 10.3390/medicina59071265. Medicina (Kaunas). 2023. PMID: 37512078 Free PMC article.
• Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications.
  Liu Y, Tong H, He F, Zhai Y, Wu C, Wang J, Jiang C. Liu Y, et al. Front Immunol. 2023 Mar 22;14:1118039. doi: 10.3389/fimmu.2023.1118039. eCollection 2023. Front Immunol. 2023. PMID: 37033957 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database